The toxic DMPK transcript in DM1-affected individuals has been identified as an active target for theraupetic intervention [7], and it is expected that breakdown of the toxic mRNA will result in at least partial reversal of DM1-induced AS changes and other known and unknown DM1-induced biomolecular pathologies. This evidence concerns the gene DMPK and myotonic dystrophy type 1.